Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
22 May 2024 - 10:00PM
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a
clinical stage biopharmaceutical company focused on developing
multimodal biological immunotherapies to help patients fight
cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci,
Candel’s President and Chief Executive Officer, will present a
company overview at the Jefferies Global Healthcare Conference on
Wednesday, June 5, 2024 at 5:30 p.m. ET.
A live webcast of the presentation will be
available by selecting Events and Presentations under the News
& Events tab in the Investors section on Candeltx.com. A replay
of the webcast will be archived for up to 90 days following the
session date.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical
company focused on developing off-the-shelf multimodal biological
immunotherapies that elicit an individualized, systemic anti-tumor
immune response to help patients fight cancer. Candel has
established two clinical stage multimodal biological immunotherapy
platforms based on novel, genetically modified adenovirus and
herpes simplex virus (HSV) gene constructs, respectively. CAN-2409
is the lead product candidate from the adenovirus platform and is
currently in ongoing clinical trials in non-small cell lung cancer
(NSCLC) (phase 2), borderline resectable PDAC (phase 2), and
localized, non-metastatic prostate cancer (phase 2 and phase 3).
CAN-3110 is the lead product candidate from the HSV platform and is
currently in an ongoing investigator-sponsored phase 1b clinical
trial in recurrent high-grade glioma (rHGG). Finally, Candel’s
enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based
discovery platform leveraging human biology and advanced analytics
to create new viral immunotherapies for solid tumors.
For more information about Candel, visit:
www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, express or implied statements
regarding the timing and advancement of development programs,
including the timing and availability of additional data; and
expectations regarding the therapeutic benefit of the Company’s
programs. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of development programs; the Company’s ability to
continue as a going concern; expectations regarding the therapeutic
benefit of the Company’s programs; that final data from the
Company’s pre-clinical studies and completed clinical trials may
differ materially from reported interim data from ongoing studies
and trials; the Company’s ability to efficiently discover and
develop product candidates; the Company’s ability to obtain and
maintain regulatory approval of product candidates; the Company’s
ability to maintain its intellectual property; the implementation
of the Company’s business model, including strategic plans for the
Company’s business and product candidates; and other risks
identified in the Company’s filings with the U.S. Securities and
Exchange Commission (SEC) including the Company’s most recent
Quarterly Report on Form 10-Q filed with the SEC and subsequent
filings with the SEC. The Company cautions you not to place undue
reliance on any forward-looking statements, which speak only as of
the date they are made. The Company disclaims any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions, or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent the Company’s views only
as of the date hereof and should not be relied upon as of the
hereof date and should not be relied upon as representing its views
as of any subsequent date.
Investor ContactTheodore
JenkinsVP Investor Relations and Business DevelopmentCandel
Therapeutics, Inc.tjenkins@candeltx.com
Media Contact:Kyle EvansICR
WestwickeCandelPR@westwicke.com
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From May 2024 to Jun 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From Jun 2023 to Jun 2024